50 related articles for article (PubMed ID: 15030987)
21. Interferon-alpha2a/ribaviran versus interferon-alpha2a alone for the retreatment of hepatitis C patients who relapse after a standard course of interferon.
Chapman BA; Stace NH; Edgar CL; Bartlett SE; Frampton CM; Scahill SL; Jennings LC
N Z Med J; 2001 Mar; 114(1128):103-4. PubMed ID: 11346153
[TBL] [Abstract][Full Text] [Related]
22. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.
González-Peralta RP; Kelly DA; Haber B; Molleston J; Murray KF; Jonas MM; Shelton M; Mieli-Vergani G; Lurie Y; Martin S; Lang T; Baczkowski A; Geffner M; Gupta S; Laughlin M;
Hepatology; 2005 Nov; 42(5):1010-8. PubMed ID: 16250032
[TBL] [Abstract][Full Text] [Related]
23. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
Mangia A; Ricci GL; Persico M; Minerva N; Carretta V; Bacca D; Cela M; Piattelli M; Annese M; Maio G; Conte D; Guadagnino V; Pazienza V; Festi D; Spirito F; Andriulli A
J Viral Hepat; 2005 May; 12(3):292-9. PubMed ID: 15850470
[TBL] [Abstract][Full Text] [Related]
24. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients.
Maddrey WC
Semin Liver Dis; 1999; 19 Suppl 1():67-75. PubMed ID: 10349694
[TBL] [Abstract][Full Text] [Related]
25. [Serious side-effects of interferon alfa and ribavirin combination therapy in patients with chronic hepatitis C].
Stránský J; Skrivánková J
Vnitr Lek; 2002 Jan; 48(1):56-9. PubMed ID: 11852590
[TBL] [Abstract][Full Text] [Related]
26. A randomized, double-blind, placebo-controlled clinical trial of high-dose interferon-alpha induction treatment combined with ribavirin for chronic hepatitis C in hemophilia.
Meijer K; Haagsma EB; van der Meer J;
J Thromb Haemost; 2004 Jan; 2(1):194-6. PubMed ID: 14717986
[No Abstract] [Full Text] [Related]
27. Combination therapy with ribavirin and interferon in a cohort of children with hepatitis C and haemophilia followed at a pediatric haemophilia treatment center.
Puetz J; Thrower M; Kane R; Bouhasin J
Haemophilia; 2004 Jan; 10(1):87-93. PubMed ID: 14962226
[TBL] [Abstract][Full Text] [Related]
28. Continued ribavirin monotherapy following interferon-ribavirin combination therapy is not effective for chronic hepatitis C.
Kakumu S
Hepatol Res; 2005 Jun; 32(2):77-8. PubMed ID: 15857808
[No Abstract] [Full Text] [Related]
29. A statistical method for removing unbalanced trials with multiple covariates in meta-analysis.
Attanasio M; Aiello F; Tinè F
PLoS One; 2023; 18(12):e0295332. PubMed ID: 38100399
[TBL] [Abstract][Full Text] [Related]
30. The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients.
Hassanein T; Shiffman ML; Zein NN
Gastroenterol Hepatol (N Y); 2007 Jun; 3(6 Suppl 20):4-32. PubMed ID: 23329897
[No Abstract] [Full Text] [Related]
31. Extended therapy with pegylated interferon and weight-based ribavirin for HCV-HIV coinfected patients.
Chung RT; Umbleja T; Chen JY; Andersen JW; Butt AA; Sherman KE;
HIV Clin Trials; 2012; 13(2):70-82. PubMed ID: 22510354
[TBL] [Abstract][Full Text] [Related]
32. Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B.
Dahari H; Guedj J; Perelson AS; Layden TJ
Curr Hepat Rep; 2011 Jul; 10(3):214-227. PubMed ID: 22180724
[TBL] [Abstract][Full Text] [Related]
33. Antiviral treatment of chronic hepatitis C in clinical routine.
Maieron A; Metz-Gercek S; Hackl F; Ziachehabi A; Fuchsteiner H; Luger C; Mittermayer H; Schöfl R
Wien Klin Wochenschr; 2010 Apr; 122(7-8):237-42. PubMed ID: 20503023
[TBL] [Abstract][Full Text] [Related]
34. Alkaline phosphatase predicts relapse in chronic hepatitis C patients with end-of-treatment response.
Bodlaj G; Hubmann R; Saleh K; Stojakovic T; Biesenbach G; Berg J
World J Gastroenterol; 2010 May; 16(19):2407-10. PubMed ID: 20480527
[TBL] [Abstract][Full Text] [Related]
35. Extended-therapy duration for chronic hepatitis C, genotype 1: the long and the short of it.
Pearlman BL
World J Gastroenterol; 2008 Jun; 14(23):3621-7. PubMed ID: 18595128
[TBL] [Abstract][Full Text] [Related]
36. Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients.
Brouwer JT; Nevens F; Bekkering FC; Bourgeois N; Van Vlierberghe H; Weegink CJ; Lefebvre V; Van Hattum J; Henrion J; Delwaide J; Hansen BE; Schalm SW;
J Hepatol; 2004 Apr; 40(4):689-95. PubMed ID: 15030987
[TBL] [Abstract][Full Text] [Related]
37. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group.
Shiffman ML; Hofmann CM; Gabbay J; Luketic VA; Sterling RK; Sanyal AJ; Contos MJ; Ryan MJ; Yoshida C; Rustgi V
Am J Gastroenterol; 2000 Oct; 95(10):2928-35. PubMed ID: 11051370
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone.
Min AD; Jones JL; Esposito S; Lebovics E; Jacobson IM; Klion FM; Goldman IS; Geders JM; Tobias H; Bodian C; Bodenheimer HC
Am J Gastroenterol; 2001 Apr; 96(4):1143-9. PubMed ID: 11316161
[TBL] [Abstract][Full Text] [Related]
39. Retreatment of hepatitis C non-responsive to interferon. A placebo controlled randomized trial of ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378].
Veldt BJ; Brouwer JT; Adler M; Nevens F; Michielsen P; Delwaide J; Hansen BE; Schalm SW;
BMC Gastroenterol; 2003 Aug; 3():24. PubMed ID: 12948399
[TBL] [Abstract][Full Text] [Related]
40. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
Davis GL; Esteban-Mur R; Rustgi V; Hoefs J; Gordon SC; Trepo C; Shiffman ML; Zeuzem S; Craxi A; Ling MH; Albrecht J
N Engl J Med; 1998 Nov; 339(21):1493-9. PubMed ID: 9819447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
